How Congressional Committees Create Information Advantages
Congressional committees are where the real work of legislation happens. They hold hearings, receive testimony from industry executives and regulators, review classified briefings, draft legislation, and mark up bills before they reach the full chamber for a vote. Committee members often develop deep expertise in their areas of jurisdiction — and they gain access to information that the general public and even most market participants do not have.
A member of the Senate Banking Committee hears directly from Federal Reserve officials, bank CEOs, and financial regulators about the state of the banking industry. A member of the Armed Services Committee receives classified briefings on defense contracts, weapons programs, and military strategy. A member of the Health, Education, Labor, and Pensions (HELP) Committee participates in hearings about drug approvals, healthcare policy, and pharmaceutical pricing.
This specialized knowledge is invaluable for legislating. It is also, potentially, invaluable for investing. The question at the heart of the committee trading conflict is straightforward: should the people who regulate industries be allowed to personally profit from trading stocks in those same industries?
Under current law, the answer is yes. The STOCK Act prohibits trading on material non-public information, but it does not prohibit members from holding or trading stocks in sectors they oversee. The distinction between “expert knowledge” and “insider information” is legally significant but practically blurry — and almost impossible to enforce.
Senate Banking Committee and Financial Stocks
The Senate Committee on Banking, Housing, and Urban Affairs has jurisdiction over the entire financial sector: banks, credit unions, securities markets, insurance, housing finance, and economic policy. Its members participate in hearings with the Federal Reserve Chair, oversee the SEC and FDIC, and shape legislation affecting every major financial institution in the country.
Multiple members of the Banking Committee have held and traded stocks in the very banks they regulate. Holdings in JPMorgan Chase, Goldman Sachs, Bank of America, Citigroup, and other major financial institutions have appeared in committee members’ disclosure filings over the years.
The conflict is not hypothetical. When the Banking Committee holds hearings on bank capital requirements, the outcome directly affects bank profitability and stock prices. When the committee marks up legislation affecting credit card fees or mortgage lending standards, committee members with bank stock holdings have a personal financial stake in the outcome. They are simultaneously writing the rules and betting on the results.
During the 2008 financial crisis, several senators with financial sector holdings participated in emergency legislation that included bailouts for institutions in which they held stock. The potential for conflicted decision-making was enormous, though no formal action was taken against any member.
Armed Services Committee and Defense Contractors
The Armed Services Committees in both chambers oversee the Department of Defense, military operations, and the defense budget — the largest discretionary spending category in the federal budget, exceeding $800 billion annually. Committee members vote on weapons programs, base closures, military contracts, and defense appropriations that directly determine the revenue of companies like Lockheed Martin, Raytheon (RTX), Northrop Grumman, General Dynamics, and Boeing.
The trading patterns are striking. Research by watchdog organizations has identified numerous instances of Armed Services Committee members buying or selling defense contractor stocks around the time of significant defense legislation or budget decisions. For a detailed analysis of this pattern, see our deep dive into defense committee trading.
The information advantage here is particularly stark. Committee members receive classified briefings on military programs, threat assessments, and acquisition strategies. They know which weapons systems are likely to receive funding increases and which face cancellation. They participate in closed-door negotiations over the National Defense Authorization Act (NDAA), the annual bill that sets defense spending priorities. This knowledge, applied to investment decisions, would constitute insider trading in virtually any other context.
Health Committees and Pharmaceutical Stocks
Health-related committees — including the Senate HELP Committee, the House Energy and Commerce Committee, and relevant appropriations subcommittees — oversee the pharmaceutical industry, FDA approvals, Medicare and Medicaid pricing, and public health policy. The pharmaceutical sector is among the most heavily regulated in the economy, making committee oversight positions exceptionally valuable from an information standpoint.
Members of these committees have traded stocks in pharmaceutical companies including Pfizer, Johnson & Johnson, AbbVie, Merck, and Eli Lilly while participating in hearings and legislation that directly affect those companies. Drug pricing bills, FDA authorization acts, and pandemic response legislation all create trading opportunities for members with both committee knowledge and pharmaceutical holdings.
The COVID-19 pandemic brought this conflict into sharp relief. Members of health committees received early briefings on the severity of the pandemic, the development of vaccines, and the government’s planned response. Some members made significant trades in pharmaceutical companies during this period. The legal line between informed policy expertise and insider trading proved nearly impossible to draw.
The Recusal Problem
Congressional rules include provisions for members to recuse themselves from votes where they have a direct personal financial interest. In theory, a member who owns stock in a defense contractor should recuse from a vote specifically affecting that contractor. In practice, the recusal system is entirely self-policing.
Members decide for themselves whether a conflict exists. There is no independent review. There is no mandatory disclosure of the reason for recusal (or the reason for not recusing). And there is a broad exception that swallows most potential conflicts: members need not recuse from votes that affect an entire class of people rather than the member individually. Since most legislation affects entire industries rather than single companies, this exception allows members to vote on virtually any bill regardless of their holdings.
A senator who owns $500,000 in bank stocks can vote on a banking regulation bill because the bill affects all bank stockholders, not just the senator. A representative who owns defense stocks can vote on the defense budget because the budget affects all defense shareholders. The class exception renders the recusal requirement meaningless for the vast majority of committee votes.
Even in the rare cases where a member does recuse, the recusal does not extend to behind-the-scenes influence. A committee member who recuses from a final vote may still participate in hearings, markup sessions, and negotiations that shape the legislation before it comes to a vote. The recusal addresses the last step of the legislative process while ignoring the steps where the most influence is exercised.
What the Research Shows
Academic research on congressional trading has consistently found patterns suggestive of information advantages. The most influential study, published by Georgia State University professor Alan Ziobrowski and colleagues in 2004, found that U.S. senators’ stock portfolios outperformed the market by approximately 12 percentage points per year during the 1993–1998 study period. A follow-up study of House members found a smaller but still statistically significant advantage.
More recent research has produced mixed results. Some studies have found that the informational advantage diminished after the passage of the STOCK Act in 2012, possibly because increased scrutiny changed behavior. Others have found that the advantage persists but is concentrated among specific subgroups — particularly committee members trading in their areas of jurisdiction.
A 2020 study published in the Journal of Financial Economics found that trades by members of committees with oversight over specific industries significantly outperformed trades in unrelated sectors. This is consistent with the hypothesis that committee-specific knowledge drives trading advantage. Members do not outperform broadly — they outperform specifically in areas where their legislative role gives them superior information.
Explore trading patterns by sector on CongressFlow’s sectors dashboard to see which industries attract the most congressional trading activity — and which committee members are the most active traders in their regulated sectors.
The Case for Reform
The committee trading conflict is arguably the strongest argument for banning individual stock trading by members of Congress. Several reform proposals have taken this approach, most notably the bipartisan TRUST in Congress Act and the Ban Conflicted Trading Act, which would require members to divest individual stock holdings or place them in qualified blind trusts.
A more targeted approach would prohibit members from trading stocks in sectors under their committee’s jurisdiction. A Banking Committee member could own technology stocks but not bank stocks. An Armed Services member could hold pharmaceutical stocks but not defense contractors. This approach would preserve members’ ability to invest in the stock market while eliminating the most direct conflicts.
Neither approach has become law. The reform bills require votes from the very members who would be restricted by them — a structural problem that has stalled every major congressional ethics reform in modern history. Until external pressure becomes overwhelming, the committee trading conflict will likely persist as one of the most visible and troubling features of congressional finance.
